Article Text

Download PDFPDF
Gemfibrozil reduced the risk for stroke in men with coronary heart disease and low concentrations of high-density lipoprotein cholesterol

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In men with coronary artery disease and low concentrations of high-density lipoprotein (HDL) cholesterol, is gemfibrozil effective for preventing stroke?


Randomised {allocation concealed*}, blinded {patients, outcome assessors, and study personnel},* placebo-controlled trial with mean 5.1 years of follow up (Veterans Affairs HDL Cholesterol Intervention Trial [VA-HIT]).


20 Veterans Affairs medical centres in the USA.


2531 men who were < 74 years of age (mean age 64 y) and had a confirmed diagnosis of coronary artery disease, an HDL cholesterol level < 1.03 mmol/l, a low-density lipoprotein cholesterol level < 3.6 mmol/l, and a triglyceride level < 3.39 mmol/l. Follow up was complete.


1264 men were allocated …

View Full Text


  • Sources of funding: Department of Veterans Affairs Office of Research and Development, and Parke-Davis.

  • For correspondence: Dr H B Rubins, Section of General Internal Medicine (1110), VAMC, Minneapolis, MN 55417, USA. Fax +1 612 725 2118.

  • * See glossary.

  • Rubins HB, Robins SJ, Collins D, et al. N Engl J Med 1999;342:410–8.

  • p Value provided by author.

  • § p Value calculated from data in article.